GLOBAL JOURNAL OF ADVANCED ENGINEERING TECHNOLOGIES AND SCIENCES

VERNONIA AMYGDALINA DELILE EXHIBITS A POTENTIAL FOR THE TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA

Clement G. Yedjou*, Jennifer N. Sims, Sylvianne Njiki, Nole Tsabang, Ifedayo V. Ogunbge, & Paul B. Tchounwou

Natural Chemotherapeutics Research Laboratory, NIH-RCMI Center for Environmental Health College of Science, Engineering and Technology, Jackson State University, 1400 Lynch Street, P.O. Box 18540, Jackson, MS, USA

DOI: 10.5281/zenodo.1343591

ABSTRACT

The World Health Organization (WHO) has been on front line to encourage developing countries to identify medicinal plants that are safe and easily available to patients. Traditional medicine represents the first-treatment choice for the healthcare of approximately 80% of people living in developing countries. Also, its use in the United States has increased by 38% during within the last decade of the 20th century alone. Therefore, the aim of the present study was to explore the efficacy of a medicinal plant, Vernonia amygdalina Delile (VAD), as a new targeted therapy for the management of acute promyelocytic leukemia (APL), using HL-60 cells as a test model. To address our specific aim, HL-60 promyelocytic leukemia cells were treated with VAD. Live and dead cells were determined by acridine orange and propidium iodide (AO/PI) dye using the Cellometer Vision. The extent of DNA damage was evaluated by the comet assay. Cell apoptosis was evaluated by flow cytometry assessment. Data obtained from the AO/PI assay indicated that VAD significantly reduced the number of live cells in a dose-dependent manner, showing a gradual increase in the loss of viability in VAD-treated cells. We observed a significant increase in DNA damage in VAD-treated cells compared to the control group. Flow cytometry data demonstrated that VAD induced apoptosis in treated cells compared to the control cells. These results suggest that induction of cell death, DNA damage, and cell apoptosis are involved in the therapeutic efficacy of VAD. Because VAD exerts anticancer activity in vitro, it would be interesting to perform clinical trials to confirm its effectiveness as an anticancer agent towards the treatment of APL patients.

KEYWORDS: Vernonia amygdalina Delile; promyelocytic leukemia (HL-60) cells; DNA damage; apoptosis.

INTRODUCTION

Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia (AML) that accounts for approximately 10-15% of nearly 12,330 adults diagnosed with AML each year in the USA [1]. The signs and symptoms of APL are nonspecific and may include the following: fatigue or feeling tired, minor infections, tendency to bleed or hemorrhagic diathesis. There is usually pancytopenia with low levels of red blood cells or anemia, low levels of the white blood cells and platelets, dyspnea, fever, thrombocytopenia, leukocytosis and coagulopathy [2]. The current treatment choice for APL is arsenic trioxide (Trisenox). Arsenic trioxide has been shown to induce complete remission in 85-86% of patients who did not respond to conventional therapy [3, 4]. Although arsenic trioxide is currently a new treatment for APL patients, the possible side effects associated with arsenic trioxide treatment includes dermatologic symptoms such as skin itching and gastrointestinal symptoms such as nausea, vomiting, and loss of appetite reported in 26.7% of patients [4]. Therefore, the development of new chemotherapeutic or chemopreventive drugs from natural products is considered important. The World Cancer Research Fund (WCRF) and the American Institute for Cancer Research (AICR) have reported that fruit and vegetable diets highly reduce the risk of several cancers including those of the mouth, pharynx, esophagus, breast, lung, pancreas, stomach, colon, rectum, and bladder [5]. Vernonia amygdalina Delile (VAD) known as bitter leaf and a species of Vernonia amygdalina (family of asteraceae) is a valuable medicinal plant that is widespread in East and West Africa [6, 7]. It has been used for many years as ethnomedicine under the recommendation of herbalists for the treatment of many diseases and disorders including stomach discomfort, vomiting, diarrhea, and intestinal illnesses in Cameroon [8, 9]. Interestingly, some of these ailments may stop in less than few hours and/or to a day after intake. These vegetables are locally available, affordable, and easily accessible to either the consumers and/or patients (Fig. 1). There is a large body of scientific reports documenting that Vernonia amygdalina has anticancer activity [9, 10, 11]; antihepatotoxic activity [12]; antibacterial activity [13]; as well as antioxidant property [14]. Recent reports from our laboratory have demonstrated that in vitro Vernonia amygdalina treatment reduces cellular viability; induces DNA damage leading to apoptosis accompanied by secondary necrosis in breast cancer cells [8, 9]. Although published studies indicate that Vernonia amygdalina has medicinal properties that are effective against many diseases, the

molecular mechanisms under which *Vernonia amygdalina* Delile (a species of *Vernonia amygdalina*) exerts its therapeutic efficacy in leukemia cells remain largely unknown. Therefore, the aim of the present study was to test the efficacy of VAD as a new targeted therapy for the management of APL, using HL-60 Promyelocytic leukemia cells as a test model.

**Figure 1:** Photo of VAD leaves taken in Bangou, West Cameroon on May 10, 2012 by Clement G. Yedjou. This photo shows how VAD leaves are processed for food: (1) Whole leaves; (2) Removal of stem and leaf veins; (3) Leaves cut in small pieces, ready to be washed several times to remove the bitter taste. After washing, it is cooked using different recipes. The production of bitter-leaves from VAD contributes to the food security and economic development in Cameroon, and helps to sustain the environment.

**RESULTS**

1. *Vernonia amygdalina* Delile Inhibits Cellular viability of HL-60 Cells

The *in vitro* cytotoxicity and anti-cancer effect of *Vernonia amygdalina* Delile (VAD) leaf extracts against HL-60 promyelocytic leukemia cells were determined by acridine orange (AO) and propidium iodide (PI) staining using the Cellometer Vision. We observed a strong dose-response relationship with regard to VAD treatment, showing a significant (*p < 0.05*) increase in the percentage of dead cells compared to the percentage of live cells in the control (Fig. 2). Acridine orange (OA) is a nuclear dye that is permeable to both live and dead cells. OA stains both live and dead nucleated cells to emit green fluorescence. Propidium iodide (PI) is a nuclear dye that is impermeable to live cells and permeable to dead cells population. PI stains all dead nucleated cells to emit red fluorescence. As seen in Fig. 2, the percentage of dead cells (red) increases with increasing doses of VAD. Fig. 3 shows the percentage of live cells as function of VAD treatment. As seen in Fig. 3, VAD is highly cytotoxic to HL-60 promyelocytic leukemia cells.

**Figure 2:** Bright field images (left) and fluorescent images (right) of HL-60 cells exposed to VAD for 24 h. Figure 2 shows HL-60 cells untreated (A-control) and HL-60 cells treated with VAD at 125 µg/mL (B), 250 µg/mL (C), and 500 µg/mL (D). Live cells (green fluorescent) and dead cells (red fluorescent) were determined based on the acridine orange and propidium iodide assay using the Cellometer Vision. The cell diameters vary from 8 to 12 µm with the average of 10 µm.
Figure 3: Antiproliferative effect of VAD to HL-60 promyelocytic leukemia cells, HL-60 cells were cultured with increasing doses of VAD (0, 125, 250, and 500 µg/mL) for 24 has indicated in the Materials and Methods. Cell viability was determined based on the acridine orange and propidium iodide assay. Each point represents a mean ± SD of 3 experiments with 6 replicates per dose. *Significantly different (p<0.05) from the control, according to the Dunnett's test.

2. Vernonia amygdalina Delile Induces DNA Damage
Representative Comet assay images of control and VAD-treated cells stained with SYBR Green are presented in Fig. 4. The percentages of DNA cleavage and tail length are represented in Fig. 5. As denoted in this figure, there is gradual increase in the mean values of comet tail length, and percentages of DNA cleavage in HL-60 cells, with increasing doses of VAD. Overall, the results generated from the comet assay indicated that VAD is highly genotoxic to HL-60 promyelocytic leukemia cells.

Figure 4: Representative SYBR Green Comet assay images of untreated (A-control) and VAD. HL-60 promyelocytic leukemia cells treated with VAD at 125 µg/mL (B), 250 µg/mL (C), and 500 µg/mL (D). A total
volume of 50 µL from 1 x 10^5 cells/mL was used for each treatment as indicated in the Materials and Methods. Untreated cells (A) showed absence of DNA migration in cultured HL-60 cells while cells treated with VAD (B, C, and D) showed clear migration of DNA from the head to tail regions.

Figure 5: Bar graph showing the percentage of DNA cleavage (A) and tail length (B) in untreated and VAD-treated HL-60 cells. A total volume of 50 µL from 1 x 10^5 cells/mL was used for each treatment as indicated in the Materials and Methods. Each point represents mean ± SD of 3 independent experiments. *Significantly different (p < 0.05) from the control, according to the Dunnett’s test.

3. Vernonia amygdalina Delile Induces Apoptosis

To prove that VAD treatment could induce apoptosis of leukemia cells, we treated HL-60 cells for 24 h. Following treatment, cells were stained with annexin V FITC/PI and analyzed by flow cytometry. We observed a strong dose-response relationship with regard to VAD treatment and annexin V positive cells (apoptotic and/or necrotic cells) (Fig. 6). As seen in Fig. 6, the percentage of apoptotic dead cells increases significantly with increasing doses of VAD compared to the control. However, a markedly decrease in annexin V positive cells was detected at 500 µg/mL VAD, probably due to a high level of cell death. Upon 24 h of exposure, the result of annexin V/PI showed that the percentages of positive annexin V cells (apoptotic cells) were 4.4 ± 4.2%, 17.4 ± 2.6%, 25.5 ± 4.8%, and 7.2 ± 2.5% in 0, 125, 250, and 500µg/mL VAD, respectively (Table 1). VAD-treated cells were significantly different (p < 0.05) at the doses of 125 and 250µg/mL according to ANOVA Dunnett’s test.

Figure 6: Representative flow cytometry analysis data from Annexin V/PI staining. The histograms show a comparison of the distribution of annexin V/PI negative cells (M1) and annexin V/PI positive cells (M2) of VAD-treated cells for 24 h. A-control; B-125µg/mL VAD; C-250µg/mL VAD; and D-500µg/mL VAD.
Table 1: Summary data of annexin V/PI assay obtained from the flow cytometry assessment. HL-60 promyelocytic leukemia cells were cultured in the absence or presence of VAD for 24 h as indicated in the Materials and Methods. Values are shown as means ± SDs of 3 replicates per experiment. *P < 0.05 versus compared with the control group.

<table>
<thead>
<tr>
<th>Concentrations</th>
<th>Annexin V/PI Negative Cells or Viable Cells (Mean ± SD)%</th>
<th>Annexin V/PI Positive Cells or Apoptotic Cells (Mean ± SD)%</th>
</tr>
</thead>
<tbody>
<tr>
<td>0μg/mL</td>
<td>95.6 ± 4.2</td>
<td>4.4 ± 4.2</td>
</tr>
<tr>
<td>125μg/mL</td>
<td>82.6 ± 2.6*</td>
<td>17.4 ± 2.6*</td>
</tr>
<tr>
<td>250μg/mL</td>
<td>74.5 ± 4.8*</td>
<td>25.5 ± 4.8*</td>
</tr>
<tr>
<td>500μg/mL</td>
<td>92.8 ± 2.5</td>
<td>7.2 ± 2.5</td>
</tr>
</tbody>
</table>

DISCUSSION

In the present study, we first tested the antiproliferative effect of VAD leaf extracts on HL-60 cells by the means of AO/PI assay using the Cellometer Vision. Our results demonstrated that VAD significantly (p<0.05) reduces the percentage of live cells in a dose-dependent manner (Fig. 2 and 3). Based on these observations, we believe that the incorporation of VAD in a person’s diet may help prevent or reduce the risk of acute promyelocytic leukemia (APL) considering the nutritional and therapeutic applications of this natural medicinal plant in many West and East Africa countries. Previous studies indicated that *Vernonia amygdalina* possesses potent antimalarial and antihelmintic properties [15], and antitumorigenic properties [16]. *Vernonia amygdalina* contains many active ingredients including Vernonioiside B and Myricetin (flavonol) [15] [17]. Oral administration of the aqueous leaf extract of *Vernonia amygdalina* has been found to relieve pain and lower body temperature [18]. Many studies have documented the beneficial use of *Vernonia amygdalina* as a potent botanical agent for the treatment of different diseases [16, 19-21]. VAD leaves (known as bitter-leaves in English) are the most consumed vegetables during special occasions including marriage, baptism, Christmas, birthday, funeral and sometimes on a daily basis in Cameroon. For example, out of 93,600 tons of leafy vegetables harvested in 1998, 21,549 tons were bitter leaf approximately 23% of the total vegetables [22]. It is well-commercialized in Cameroon both for its health promoting benefit as a medicinal plant and for its nutritional value. Scientific data indicated that *Vernonia amygdalina* contains significant quantities of lipids, proteins with high essential amino acid content, and fiber [23]. It also possesses carbohydrates, high level of vitamin C, and carotenooids [24]. In 2015, our research group used diverse medicinal plants to treat 328 Cameroonian patients who have been diagnosed at least once by a physician or medical professional with diabetes and/or hypertension for 10 days. At the end of the 10 days treatment, we found that 70% of patients have a complete remission and were free from diabetes and/or hypertension [25].

Next, the comet assay, also known as single cell gel electrophoresis (SCGE) was used to detect DNA damage in VAD-untreated and treated cells. We found that VAD has strong genotoxic damage potential and is able to cause DNA damage in leukemia cells. Our results demonstrated that VAD induces genotoxic effects to HL-60 promyelocytic leukemia cells in a dose-dependent fashion; suggestive clear evidence that VAD is a potent DNA damage inducer in HL-60 cells. It is well known that DNA damage is the underlying cause of many diseases such as cancer, diabetes, and hypertension. Therefore, the results of the current study suggest that VAD may have potential for the prevention and treatment of these diseases.

http://www.gjaets.com/
damaging agent against APL. Similarly, other studies in our laboratory showed that the size, shape and distribution of DNA within the comet correlate with the extent of DNA damage in human promyelocytic leukemia cells when treated with arsenic trioxide [26, 27]. There are limited scientific data in the literature explaining how VAD induces DNA damage in leukemia cells. Hence, further studies are needed to establish the genotoxic mechanism on the basis of the genetic damage induced by VAD. Thus, we show in the present study that even at a relatively low dose VAD leaf extracts induce DNA damage in HL-60 promyelocytic leukemia cells. It has been reported that agents that have the ability to cause minimal DNA damage are generally good candidates for cancer therapy [28, 29]. On the other hand, agents that cause cell damage but not cell death, causes sustained DNA damage, and are therefore possible mutagens and/or carcinogens [30].

To explore whether VAD induces apoptosis of HL-60 promyelocytic leukemia cells, we stained the cells with annexin VFITC/PI antibodies and analyzed by flow cytometry assessment. Annexin V binds to the membrane phospholipid phosphatidylserine that is located within the plasma membrane of apoptotic cells and PI is a nuclear dye that is impermeable to live cells and permeable to dead cells population. PI stains all dead nucleated cells [31]. Data generated from the flow cytometry assessment demonstrated that VAD induced apoptosis of HL-60 promyelocytic leukemia cells in a dose-dependent fashion. The percentage of cells stained with Annexin V (positive cells) and PI (necrotic cells) significantly (P < 0.05) increased with the increasing doses of VAD (Fig. 6). By the means of flow cytometry assessment, we were able to show that VAD induced apoptosis and/or necrosis in HL-60 promyelocytic leukemia cells via phosphatidylserine externalization as result of the loss of membrane integrity, a major characteristic of cell death by apoptosis and/or necrosis. These observations are in agreement with a report in which Vernonia amygdalina was shown to alter the cell membrane permeability in MCF-7 cells [32]. Another report indicated that Vernonia amygdalina increased the number of apoptotic cells as demonstrated by the Annexin V-FITC/PI assay [33]. Rupture of the cellular membrane is one of the crucial criteria used to distinguish necrosis from apoptosis [34].

METHODS

1. Chemicals and Media
   Growth medium RPMI 1640 containing 1mmol/L L-glutamine was purchased from Gibco BRL products (Grand Island, NY). Fetal bovine serum (FBS), phosphate buffered saline (PBS), and acridine orange and propidium iodine were obtained from Sigma Chemical Company (St. Louis, MO). Annexin V/PI kit was obtained from BD Biosciences (Pharmingen, Becton Dickinson Co., San Diego, CA, USA).

2. Vernonia amygdalina Delile Preparation
   Vernonia amygdalina Delile leaves (4-5 kg) were collected in Bangou, West Cameroon. They were rinsed with distilled water and dried under the sun. Briefly, 100 g of dried leaves were added to 1200 mL of methanol. The mixture was heated at 50°C for 6 h. The mixture was filtered with cheesecloth and later with Whatman No. 1 filter paper to obtain a homogenous filtrate. Excess solvents were trapped, collected and removed from the filtrate using a rotary evaporator. The extracts were then refrigerated at 4°C until use. The preparation was done in the Department of Chemistry and Biochemistry at Jackson State University.

3. Tissue/Cell Culture
   HL-60 promyelocytic leukemia cells were purchased from the American Type Culture Collection-ATCC (Manassas, VA). These have been derived from peripheral blood cells of a 36-year old Caucasian female with acute promyelocytic leukemia (APL). In the laboratory, cells were stored in the liquid nitrogen until use. They were next thawed by gentle agitation of their containers (vials) for 2 min in a water bath at 37°C. After thawing, the content of each vial of cell was transferred to a 25 cm² tissue culture flask, diluted with up to 10 mL of RPMI 1640 containing 1 mmol/L L-glutamine (GIBCO/BRL, Gaithersburg, MD) and supplemented with 10% (v/v) fetal bovine serum (FBS), 1% (w/v) penicillin/streptomycin. The 25 cm² culture flasks (2 x 10⁶ viable cells) were observed under the microscope, followed by incubation in a humidified 5% CO₂ incubator at 37°C. Three times a week, they were diluted under same conditions to maintain a density of 5 x 10⁵/mL, and harvested in the exponential phase of growth. The cell viability was assessed by the trypan blue exclusion test (Life Technologies), and manually counted using a hemocytometer.

4. Cell Treatment and Determination of Cell Viability
   To determine the anti-proliferative effects of VAD in vitro, 1 x 10⁶ cells/mL were washed with PBS and treated with different doses of VAD and placed in the humidified 5% CO₂ incubator for 24h. The cells incubated in
culture medium alone served as a control for cell viability (untreated wells). To determine the anti-proliferative
effects of VAD in vitro, 900 µL aliquots in six replicates of the cell suspension (1 x 10⁶ cells/mL) were added to
12-well polystyrene tissue culture plates, 100 µL aliquots of stock solutions were added to each well using
distilled water as solvent to make-up final VA doses of 0, 125, 250, and 500 µg/mL. Control cells received 100 
µL of distilled water. Cells were placed in a humidified 5% CO₂ incubator for 24 h at 37°C. After incubation,
the live and dead cells were determined by acridine orange and propidium iodide (AO/PI) staining using the
Cyclometer Vision. To perform this experiment, 25 µL of AO/PI dye was added to 25 µL of cell suspension
taken from each sample. Samples were gently mixed and 20µL of cell suspension was loaded into the
cellometer counting chamber. The cellometer counting chamber was placed into the Cellometer Vision and both
cell concentration and viability were determined using the Vision software as previously described [35].

5. Detection of DNA Damage by the Comet Assay
The comet assay was carried out by the method previously described by Collins and his collaborators [36, 37] with some modifications [26]. Briefly, 1 x 10⁶ cells/mL were treated with either media or VAD (0, 125, 250, and 500 µg/mL) respectively and incubated in a 5% CO₂ at 37°C for 24 h. After incubation, the cells were
centrifuged, washed with PBS, and 1 x 10⁵ cells/mL counted from the pool of untreated and treated cells were
used for the assay. In a 2 mL tube, 50 µL of the cells suspension and 500 µL of melted LMAgarose were mixed and
75 µL was pipetted onto a pre-warmed cometslide. The side of the pipette tip was used to spread agarose/cells over the sample area completely. The slides were then placed flat in the dark at 4°C for 10 minutes to allow the mixture to solidify and then immersed in prechilled lysis solution at 4°C for 40 minutes. Next, the slides were removed from lysis solution, tapped, and immersed in Alkaline Solution for 40 minutes at room
temperature in the dark. The slides were washed twice for 5 min with Tris
Hepes/NaOH pH 7·4, 140 m
CaCl₂), and stained with FITC
and PI) and necrotic cells (stained with both annexin-V and PI) [31]. Briefly, 1 x 10⁶ cells/mL were washed in PBS, re-suspended in binding buffer (10 mM Hepes/NaOH pH 7-4, 140 mM NaCl, 2-5 mM CaCl₂), and stained with FITC-conjugated annexin V
(Pharmingen, Becton Dickinson Co., San Diego, CA, USA). Then, cells were incubated for 15 min in the dark at
room temperature, washed with binding buffer and analyzed by flow cytometry (FACS Calibur; Becton-
Dickinson) using CellQuest software.

6. Detection of Apoptosis by the Annexin V FITC/PI Assay
To evaluate apoptosis of HL-60 Promyelocytic leukemia cells exposed to VAD, we performed the Flow
Cytometry assessment using annexin V FITC/PI staining kit. Annexin-V binds to cells that express
phosphatidylserine on the outer layer of the cell membrane, and PI stains the cellular DNA of those that have a
compromised cell membrane. This allows for the discrimination of live cells (unstained with either
fluorochrome) from apoptotic cells (stained only with annexin-V) and necrotic cells (stained with both annexin-
V and PI) [31]. Briefly, 1 x 10⁶ cells/mL were washed in PBS, re-suspended in binding buffer (10 mM Hepes/NaOH pH 7-4, 140 mM NaCl, 2-5 mM CaCl₂), and stained with FITC-conjugated annexin V
(Pharmingen, Becton Dickinson Co., San Diego, CA, USA). Then, cells were incubated for 15 min in the dark at
room temperature, washed with binding buffer and analyzed by flow cytometry (FACS Calibur; Becton-
Dickinson) using CellQuest software.

7. Statistical Analysis
Experiments were performed in triplicates. Data were presented as means ± SDs. Where appropriate, one-way ANOVA or Student paired t-test was performed using SAS Software available in the Biostatistics Core Laboratory at Jackson State University. P-values less than 0.05 were considered statistically significant.

CONCLUSIONS
Medicinal plants have served as valuable starting materials for drug development in both developing and
developed countries. Knowing that many pharmacologically active drugs are derived from medicinal plants [38, 39], our goal in the present work was to test the therapeutic efficacy of Vernonia amygdalina Delile (VAD)
towards the treatment of acute promyelocytic leukemia, using HL-60 promyelocytic leukemia cells as test
model. Our results demonstrated that VAD has anti-cancer effects against HL-60 promyelocytic leukemia cells.
The effect was mediated through the inhibition of cell proliferation of the HL-60 promyelocytic leukemia cells.
A novel finding was that the underlying mechanisms by which VAD induced growth inhibition of HL-60
promyelocytic leukemia cells involved the induction of cell death, DNA damage, and cell apoptosis. These
results suggest that VAD can act as a complement to the current treatment for APL patients. Because VAD
exerts anticancer activity in vitro, it would be interesting to perform clinical trials to confirm its effectiveness as
an anticancer agent towards the treatment of patients with APL.
ACKNOWLEDGMENTS
The research described in this publication was made possible by a grant from the National Institutes of Health (Grant No. NIMHD-G12MD007581) through the RCMI-Center for Environmental Health at Jackson State University.

Author Contributions
CGY, JNS, and SN conceived, designed, and drafted the manuscript. NT, IVO and PBT participated in the implementation of the study, acquisition, analysis and interpretation of data. All the authors have read and approved the final manuscript.

Conflicts of Interest
The authors declare no conflict of interest

REFERENCES


